Mochi Health Tirzepatide Cost: What You Actually Pay in 2026

What does Mochi Health cost per month?

Mochi runs on a two-part billing structure: a monthly membership fee billed separately from a monthly medication fee. The membership is $79 a month and covers the clinical care platform — board-certified physician visits, registered dietitian coaching, 24/7 messaging, and ongoing monitoring. The medication is charged on top of that.

• Compounded semaglutide (injection, oral tablet, or oral drops): $99/mo medication + $79/mo membership = $178/mo total
• Compounded tirzepatide: $199/mo medication + $79/mo membership = $278/mo total
• Branded GLP-1 (Wegovy, Ozempic, Zepbound, Mounjaro): medication cost varies; $79/mo membership still applies
• Shipping: included in all medication prices — no separate delivery charge

The membership can be discounted with a bulk prepay: three months for $199 (about $66/mo effective), six months for $399, or twelve months for $799 — the annual plan works out to roughly $66.58/mo for the membership component. The medication subscription continues to bill monthly on its own cycle regardless of how you pay for the membership. Prices verified at joinmochi.com, Jun 16, 2026.

Does the price go up as my dose increases?

No — and this is the part of Mochi's model that most directly separates it from competitors. Most GLP-1 telehealth platforms charge you more as your dose titrates upward, because higher doses require more drug volume from the pharmacy. Mochi absorbs that cost differential and holds the line at $99/mo for semaglutide and $199/mo for tirzepatide, from your starting dose through your full maintenance dose.

For comparison: several competitors raise their price at the maintenance tier. At Mochi, a patient going from a starter dose to maintenance pays the same amount throughout. Over a 12-month course, that difference can add up to several hundred dollars for patients who need higher doses to reach or sustain their goals.

What does the $79 membership actually cover?

The membership is the care infrastructure layer. It gives you access to Mochi's physician network — all ABOM-certified, meaning board-certified specifically in obesity medicine, not just general practice. That's a meaningful clinical differentiator: ABOM physicians complete training in the metabolic science of weight regulation and hormonal health, which matters for perimenopausal patients dealing with both.

The $79 also covers regular video visits with that physician, access to a registered dietitian on your care team, 24/7 secure messaging, and a patient portal for booking and prescription tracking. Options for labs, genetic testing, and sleep apnea assessments are listed as add-ons, not automatic inclusions — if your provider recommends baseline bloodwork, you pay for that separately or order through your own primary care provider.

• Included: video visits with an ABOM-certified physician
• Included: registered dietitian on your care team
• Included: 24/7 messaging, patient portal, ongoing care monitoring
• Included: prescription access at any dose level
• Not included: medication (billed separately at $99 or $199/mo)
• Not included: lab work as standard — available as an optional add-on
• Not included: insurance billing (Mochi is cash-pay for both membership and medication)

HSA and FSA cards are accepted at checkout for the membership fee. Mochi also prepares a superbill receipt on request, which you can submit to your insurer for potential partial reimbursement of care costs. Whether the medication fee qualifies for HSA/FSA depends on your plan administrator — it's worth confirming before you assume coverage on the medication side.

How much is Mochi Health per year — the full annual math

On a standard month-to-month membership, the all-in annual cost breaks down simply:

• Semaglutide track: $178/mo x 12 = $2,136/yr
• Tirzepatide track: $278/mo x 12 = $3,336/yr
• Annual membership prepay saves $149/yr on the membership alone ($948 standard vs. $799 annual rate)

Labs are the most likely additional cost. A basic metabolic panel and lipid panel through a direct-pay lab typically runs $40-$100 per draw, and most GLP-1 providers recommend checking metabolic markers at baseline and at least once more during the first year. Budget an additional $100-$400 annually for monitoring bloodwork if your primary care provider isn't covering it.

For perimenopausal and menopausal women, first-year lab costs often run higher. A broader hormonal and metabolic baseline — estrogen, FSH, thyroid panel, HbA1c, lipids — can run $150-$300 at a direct-pay lab depending on the panel. If you're starting GLP-1 therapy alongside or before considering hormone therapy, that baseline is useful to have regardless of who's prescribing it.

How does Mochi Health's price compare to competitors?

Mochi's flat-rate advantage is clearest in a direct comparison. Here's how the major compounded GLP-1 platforms line up for a patient seeking tirzepatide or semaglutide on a month-to-month cash-pay basis.

Henry Meds — $249-$449/mo, no separate membership

Henry Meds builds everything — physician visits, supplies, shipping — into a single subscription with no separate membership fee, which simplifies the billing model. Injectable semaglutide runs $297/mo, oral semaglutide $249/mo, and tirzepatide injectable $449/mo. For patients who can commit to a year up front, Henry's annual rates come down; for patients who titrate to higher doses, Mochi's flat rate typically wins. Full details in the Henry Meds review.

Fridays — $150-$359/mo depending on commitment length

Fridays bundles compounded medication, physician visits, dietitian coaching, a fitness app, and 24/7 messaging into one subscription. Compounded semaglutide starts at $199/mo month-to-month and drops to $150/mo on an annual prepay ($1,800 billed upfront); tirzepatide runs $359/mo monthly or $240/mo annually. The annual semaglutide rate is the lowest all-in price on this comparison, but it requires a large upfront commitment with limited refund flexibility if you need to stop. Month-to-month, Mochi is competitive on both molecules. The Fridays review covers the full program in depth.

Hers — ~$298-$448/mo all-in, women-focused

Hers is built specifically for women, which makes it a natural alternative for perimenopausal patients who want a platform oriented around female physiology and hormonal health. It now centers on brand-name GLP-1s — the Wegovy pill and pen and the Zepbound vial — rather than compounded semaglutide, and the Weight Loss Membership adds $39 for the first month and then $149/mo after that. All-in, most Hers members pay ~$298-$448/mo (brand Wegovy pill/pen; Zepbound higher) — above Mochi's comparable tiers across the board. Whether the women-first clinical framing justifies the premium depends on what you're looking for beyond GLP-1 access. See the Hers review for the full breakdown.

The short summary: Mochi is the most cost-competitive option for month-to-month tirzepatide and holds its own on semaglutide. If you can commit to an annual prepay and want everything bundled, Fridays' semaglutide annual plan undercuts it. If you want all-in pricing without a separate membership fee, Henry Meds is worth modeling for your expected dose tier.

Any hidden fees or billing surprises to know about?

Mochi's pricing is clearly stated, but the dual-subscription structure is consistently the platform's biggest consumer friction point. The membership and the medication are two independent recurring charges that renew and cancel on separate cycles. Canceling one does not cancel the other. A large share of consumer complaints centers on this exact issue: patients who believed they had canceled everything found themselves billed again because only one of the two subscriptions was terminated.

Mochi's refund policy adds to the friction. Refunds are generally not issued after 24 hours of payment, and prescription orders are considered final once medication has been dispatched to the pharmacy. If your circumstances change mid-month — a new pregnancy, a contraindication, a change in provider direction — you are likely past the refund window for that billing cycle.

• Membership and medication are two separate subscriptions — you must cancel both explicitly to stop all billing
• Refund window: 24 hours from payment; medication is non-refundable once sent to pharmacy
• Labs: not included as standard; billed as an add-on if ordered through Mochi
• Insurance: not accepted for membership or compounded medication costs
• Shipping: included in medication prices, no separate fee

The Aequita pharmacy closure — what happened and where Mochi stands now

In March 2025, Washington State issued a Notice of Immediate Jeopardy against Aequita Pharmacy, one of Mochi's primary compounding partners at the time, citing sterile compounding violations that included unlicensed workers handling medications. The pharmacy ceased operations, and Mochi patients relying on Aequita for their GLP-1 supply experienced disruptions and delays.

Mochi has since expanded its pharmacy network to over 33 partners. A patient starting with Mochi today will not be dispensed medication through Aequita, which is no longer active. That said, the closure was a serious event, and it raised questions about pharmacy oversight that are worth weighing. Asking your provider which specific pharmacy will fill your prescription — and verifying that pharmacy holds current state licensure — is a reasonable due-diligence step.

There is also an ongoing civil matter: Eli Lilly filed suit against Mochi Health alleging unfair competition in how it marketed compounded tirzepatide. An initial complaint was dismissed in October 2025. An amended complaint was filed, and in April 2026 a federal judge allowed Lilly's claims under California's Unfair Competition Law and the federal Lanham Act to proceed. This is active litigation with no final ruling.

The FDA 503B proposed rule — real risk or distant threat?

On April 30, 2026, the FDA proposed to remove semaglutide, tirzepatide, and liraglutide from the 503B bulk compounding list, concluding that the drug shortage justification that originally opened the door to large-scale compounding no longer applies. The public comment period closed June 29, 2026. No final rule has been issued as of this writing.

If finalized, the rule would prohibit 503B outsourcing facilities from compounding these drugs from bulk substances. The practical impact on Mochi depends on which legal category its pharmacy partners operate under. 503B facilities are the direct target; 503A compounding pharmacies — which operate under patient-specific prescriptions from a licensed physician — follow a distinct regulatory pathway that is not directly covered by this proposed rule. Patients should ask their Mochi provider which type of facility is filling their specific prescription.

For current patients: Mochi continues to dispense compounded GLP-1 medications, and pricing has not changed in response to the proposal. This is a medium-term supply risk that warrants monitoring, not an immediate disruption.

Is Mochi Health worth the cost for perimenopausal women?

For patients who expect to titrate to maintenance doses — which describes most people on a GLP-1 program — Mochi's flat-rate structure is a real financial advantage. At $278/mo all-in for tirzepatide with ABOM-certified physician oversight, a registered dietitian, and 24/7 messaging, the price-to-care ratio is competitive against every platform in this space. The four semaglutide formats (injection, oral tablet, drops, microdose) also give Mochi more format flexibility than most competitors.

For perimenopausal and menopausal women specifically: Mochi's metabolically oriented providers are experienced with patients navigating the hormonal shifts that accompany this stage — insulin sensitivity changes, the relationship between estrogen decline and fat redistribution, the interaction between GLP-1 therapy and menopause symptoms. The platform does not prescribe hormone therapy, so if you're managing both, you'll need a separate HRT provider. That's a practical gap, not a clinical concern.

The honest caveats: the dual-subscription billing requires careful management at cancellation, lab monitoring is not included, the pharmacy track record carries a documented blemish, and the regulatory environment for compounded GLP-1s is in active flux. None of those are reasons to avoid the platform outright — but each is worth knowing before you start.